Trial · NCT00548548
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival | Bevacizumab | 12.1 | 95% Confidence Interval 11.1 to 13.8 | months | |
| Overall Survival | Placebo | 10.1 | 95% Confidence Interval 9.0 to 11.3 | months | |
| Progression-free Survival | Bevacizumab | 6.7 | 95% Confidence Interval 5.9 to 7.1 | months | |
| Progression-free Survival | Placebo | 5.3 | 95% Confidence Interval 4.4 to 5.6 | months | |
| Progression-free Survival During First-line Therapy | Bevacizumab | 6.9 | 95% Confidence Interval 6.2 to 7.3 | months | |
| Progression-free Survival During First-line Therapy | Placebo | 5.4 | 95% Confidence Interval 4.7 to 5.6 | months | |
| Time to Disease Progression | Bevacizumab | 7.0 | 95% Confidence Interval 6.5 to 7.6 | months | |
| Time to Disease Progression | Placebo | 5.6 | 95% Confidence Interval 5.1 to 5.8 | months | |
| Participants With a Best Overall Response of Complete or Partial Response | Bevacizumab | Responders | 143 | participants | |
| Participants With a Best Overall Response of Complete or Partial Response | Placebo | Responders | 111 | participants | |
| Participants With a Best Overall Response of Complete or Partial Response | Bevacizumab | Non-responders | 168 | participants | |
| Participants With a Best Overall Response of Complete or Partial Response | Placebo | Non-responders | 186 | participants | |
| Duration of Response | Bevacizumab | 7.1 | 95% Confidence Interval 6.2 to 8.3 | months | |
| Duration of Response | Placebo | 5.8 | 95% Confidence Interval 4.6 to 6.9 | months | |
| Participants With Disease Control | Bevacizumab | Participants with Disease Control | 300 | participants | |
| Participants With Disease Control | Placebo | Participants with Disease Control | 271 | participants | |
| Participants With Disease Control | Bevacizumab | Participants without Disease Control | 87 | participants | |
| Participants With Disease Control | Placebo | Participants without Disease Control | 116 | participants | |
| Participants With Adverse Events | Bevacizumab | Any Adverse event | 380 | participants | |
| Participants With Adverse Events | Placebo | Any Adverse event | 377 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00548548/results